Benzinga · Mar 10, 2026
ON
NASDAQ · ONCO
Onconetix, Inc.
Healthcare · Biotechnology
$0.78
Down-$0.03 (-3.81%)
Updated Sep 11, 2026, 7:51 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.31M
- P/E ratio
- -0.07
- Dividend yield
- 0.00%
- 52-week range
- $0.36 – $20.95
- Volume
- 172.91K
- Avg. volume
- 114.33K
Price performance
ONCO price history
1M range · 20 trading sessions · Daily adjusted prices
ONCO closed at $0.78 after 20 trading sessions, down 11.36% for the selected period.
- Last close
- $0.78
- Period change
- -11.36%
- Period low
- $0.61
- Period high
- $1.02
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $0.8186 | $0.8439 | $0.767 | $0.7822 | 172.91K |
| Sep 9, 2026 | $0.835 | $0.835 | $0.8006 | $0.8132 | 266.11K |
| Sep 8, 2026 | $0.8611 | $0.95 | $0.82 | $0.84 | 1.26M |
| Sep 4, 2026 | $0.7385 | $1.05 | $0.7106 | $1.02 | 6.66M |
| Sep 3, 2026 | $0.6818 | $0.7445 | $0.6601 | $0.739 | 289.13K |
| Sep 2, 2026 | $0.62 | $0.7034 | $0.62 | $0.6743 | 98.32K |
| Sep 1, 2026 | $0.6192 | $0.69 | $0.6192 | $0.6528 | 127.32K |
| Aug 31, 2026 | $0.60 | $0.64 | $0.5868 | $0.6268 | 153.66K |
| Aug 28, 2026 | $0.628 | $0.6439 | $0.61 | $0.6123 | 91.48K |
| Aug 27, 2026 | $0.65 | $0.65 | $0.632 | $0.632 | 101.29K |
| Aug 26, 2026 | $0.6449 | $0.6558 | $0.64 | $0.641 | 80.07K |
| Aug 25, 2026 | $0.64 | $0.66 | $0.64 | $0.643 | 106.84K |
| Aug 24, 2026 | $0.65 | $0.6572 | $0.6333 | $0.656 | 353.53K |
| Aug 21, 2026 | $0.651 | $0.666 | $0.6207 | $0.6505 | 225.62K |
| Aug 20, 2026 | $0.6897 | $0.71 | $0.66 | $0.667 | 231.25K |
| Aug 19, 2026 | $0.7478 | $0.7478 | $0.6993 | $0.711 | 320.59K |
| Aug 18, 2026 | $0.76 | $0.7979 | $0.71 | $0.7503 | 737.6K |
| Aug 17, 2026 | $0.807 | $0.807 | $0.7402 | $0.7575 | 159.85K |
| Aug 14, 2026 | $0.88 | $0.88 | $0.8113 | $0.8113 | 236.76K |
| Aug 13, 2026 | $0.905 | $0.9261 | $0.8801 | $0.8824 | 44.47K |
Latest ONCO news
The latest Smart Investors Daily articles mentioning ONCO.
Stock researchCompany · Overview
ONCO research
Overview
Company profile and research snapshot.
Company profile
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
ChartMill · Feb 13, 2026
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
SeekingAlpha · Feb 13, 2026
Onconetix, Inc. (ONCO) M&A Call Transcript
Onconetix, Inc. (ONCO) M&A Call February 13, 2026 2:00 PM ESTCompany ParticipantsJennifer Karkula - Head of CommunicationsAndrew Kiguel - Co-Founder,...
Benzinga · Feb 13, 2026
Is Onconetix Inc Gaining or Losing Market Support?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
